<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://rememberingbaltimore.net/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=ArnoldOquinn6</id>
	<title>Ecpclio Research &amp; Writing - User contributions [en]</title>
	<link rel="self" type="application/atom+xml" href="https://rememberingbaltimore.net/api.php?action=feedcontributions&amp;feedformat=atom&amp;user=ArnoldOquinn6"/>
	<link rel="alternate" type="text/html" href="https://rememberingbaltimore.net/index.php/Special:Contributions/ArnoldOquinn6"/>
	<updated>2026-11-22T02:59:13Z</updated>
	<subtitle>User contributions</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://rememberingbaltimore.net/index.php?title=We_Strive_To_Attract&amp;diff=20755</id>
		<title>We Strive To Attract</title>
		<link rel="alternate" type="text/html" href="https://rememberingbaltimore.net/index.php?title=We_Strive_To_Attract&amp;diff=20755"/>
		<updated>2026-09-10T12:45:42Z</updated>

		<summary type="html">&lt;p&gt;ArnoldOquinn6: Created page with &amp;quot;&amp;lt;br&amp;gt;People and culture are core to our business and global success. We are deeply invested in people who want to make things happen, who have big visions and  [http://aiwadata.com/bbs/board.php?bo_table=free&amp;amp;wr_id=5226618 MedicGLP Online] practical know-how, and who have what it takes to challenge convention and push businesses and industries forward. We are entrepreneurial, growth focused and have a winning mindset to be the best. We encourage our people to think beyond...&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;People and culture are core to our business and global success. We are deeply invested in people who want to make things happen, who have big visions and  [http://aiwadata.com/bbs/board.php?bo_table=free&amp;amp;wr_id=5226618 MedicGLP Online] practical know-how, and who have what it takes to challenge convention and push businesses and industries forward. We are entrepreneurial, growth focused and have a winning mindset to be the best. We encourage our people to think beyond the bounds of their role and our industry and pursue innovation, share new ideas and  [http://singsingco.kr/bbs/board.php?bo_table=free&amp;amp;wr_id=126230 MedicGLP Website] work as a team. Our leadership empowers employees at all levels to have big ideas. We believe in bringing together different skill-sets and mindsets leads to better outcomes. We encourage our employees to think about how their actions and decisions can add the most value. We focus on [https://www.groundreport.com/?s=maintaining maintaining] a small company identity with an entrepreneurial mindset. Our passion for winning means new ideas and fresh thinking are vital to our long-term success.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Thinking like an entrepreneur requires you to take action, accept responsibility for your decisions, improving your skills, and where necessary learning from mistakes, to achieve the best outcome. GLP engages in performance reviews and talent development initiatives including on-the-job experience, exposure and education that align with individual career development plans. We have a strong focus toward gaining experience through real-time development, especially when knowledge exists but practical application is required. We want to give individuals the option to expand their scope and responsibilities by giving them access to mentorship, stretch projects, higher duties or acting roles, job rotation and/or secondments. GLP is a global company with offices around the world that share the same values, and strives to create an inclusive environment which embraces diversity and fosters inclusion. We see tremendous value in and are strongly committed to having a well-rounded, inclusive workplace starting from recruitment all the way to leadership training. We strive to attract, develop, retain, and promote the best talent - people from diverse backgrounds with unique knowledge bases,  [https://maxmeta.io/index.php/Does_Victoza_Help_With_Weight_Loss:_Results,_Side_Effects MedicGLP Online] interests, cultural identities and skill sets.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Science continues to prove that the old adage &amp;quot;you are what you eat&amp;quot; is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your &amp;quot;gut microbiota.&amp;quot; They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;1. Unable to lose weight and keep it off? 2. Struggling to fight cravings? 3. Sick of starving yourself for weight loss? 4. Baffled as to why no diet seems to really work for you? Depending on the composition of your gut microbiome, your microbes can either boost your health or weigh you down (figuratively and literally). The good news is this: You have control over these little guys with every bite you eat. Diet has the power to change the landscape of your gut microbiome. So, if you’ve tried multiple diets and can’t seem to get the results you want, it’s time to look into your [https://www.hometalk.com/search/posts?filter=gut%20microbiome gut microbiome].Will You Lose Weight Naturally on an Individualized Diet? If you’ve been struggling to lose weight and keep it off - it could be your gut microbiome. While Viome doesn’t guarantee weight loss,  [http://www.dahengsi.com:30002/meribeaty20087 MedicGLP] it has been an exciting result many of our customers have reported. &amp;quot;Fiona’s update day 37!&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;We know weight loss can be tough. Find out if your weight struggles are due to a gut microbiome imbalance with Viome - and let’s tip the scales in your favor. Your gut microbes actually digest much of your food for you. When your gut microbiota help digest your food, they turn it into nutrients, neurotransmitters, vitamins, hormones, and more. Through these metabolites, the composition of your gut microbiome influences nearly every metabolic activity. It’s accurate to think of your gut microbiome as an organ that’s part immune system and part energy regulator. If your gut microbiome is imbalanced, certain bacteria end up working to protect themselves from the harsh environment and are not able to help you. In the worst case scenario, you can have microbiota adding to your health problems, making it harder for you to get healthy and lose weight. Viome’s metatranscriptomic technology has allowed us identify microbial pathways and functions, specifically those that influence weight loss or gain.&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>ArnoldOquinn6</name></author>
	</entry>
	<entry>
		<id>https://rememberingbaltimore.net/index.php?title=WHO_Unveils_First_Global_Standards_For_GLP-1_Weight-Loss_Drugs,_Marking_Major_Shift_In_Obesity_Treatment&amp;diff=20259</id>
		<title>WHO Unveils First Global Standards For GLP-1 Weight-Loss Drugs, Marking Major Shift In Obesity Treatment</title>
		<link rel="alternate" type="text/html" href="https://rememberingbaltimore.net/index.php?title=WHO_Unveils_First_Global_Standards_For_GLP-1_Weight-Loss_Drugs,_Marking_Major_Shift_In_Obesity_Treatment&amp;diff=20259"/>
		<updated>2026-09-10T06:41:45Z</updated>

		<summary type="html">&lt;p&gt;ArnoldOquinn6: Created page with &amp;quot;&amp;lt;br&amp;gt;In a landmark move, the World Health Organization has issued its first global guideline for the use of GLP-1-based weight-loss medicines, officially recognizing the drugs as an important tool in modern obesity care. The guidance, released Monday, signals a major policy evolution for the health agency as demand for medications like semaglutide and tirzepatide continues to rise worldwide. The WHO now recommends GLP-1 receptor agonists for adults with a body mass index...&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;In a landmark move, the World Health Organization has issued its first global guideline for the use of GLP-1-based weight-loss medicines, officially recognizing the drugs as an important tool in modern obesity care. The guidance, released Monday, signals a major policy evolution for the health agency as demand for medications like semaglutide and tirzepatide continues to rise worldwide. The WHO now recommends GLP-1 receptor agonists for adults with a body mass index of 30 or above, or for individuals with a BMI of at least 27 who also live with conditions linked to excess weight, including type 2 diabetes, hypertension, abnormal cholesterol levels, or sleep-related breathing disorders. However, the agency stresses that the drugs must not be used in isolation. According to the guideline, treatment should be delivered as part of a broader clinical plan involving nutrition support, physical activity programs,  [https://ctpedia.org/index.php/Good_Laboratory_Practice_(GLP) MedicGLP] behavioral counseling, and other medical care where appropriate. The new recommendation is grounded in a comprehensive evidence review, which showed that GLP-1 therapies paired with lifestyle changes consistently produced stronger weight-loss outcomes and improved cardiovascular results compared to lifestyle interventions alone.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Despite the promising data, WHO officials expressed serious concern about limited global availability. The organization warned that high prices and persistent supply shortages have created significant barriers, raising the risk that only wealthier populations will benefit from the treatments. &amp;quot;GLP-1 medicines represent real progress, but they cannot be allowed to widen the gap in global health,&amp;quot; said the head of the WHO’s Department of Nutrition and Food Safety. He noted that without sustained efforts to expand  [http://www.365rise.top/renepowell8343/1331medicglp/wiki/I-Tried-GLP-1s-for-Weight-Loss:-6-Things-i-Wish-i-Knew-before-Starting MedicGLP.com] access, the global response to obesity could become increasingly unequal. To address these challenges, the guideline urges governments and manufacturers to pursue price negotiations, voluntary licensing, and technology-transfer agreements that would support lower-cost production and improve availability in low- and middle-income countries. The directive also highlights commonly reported side effects such as nausea, vomiting, and constipation, emphasizing the importance of medical supervision throughout treatment. WHO experts caution that the medicines are powerful but require careful monitoring to ensure safe, long-term use. The release of the guideline marks the first time the WHO has formally endorsed a pharmacological approach to obesity on a global scale. With obesity rates continuing to climb across regions, the organization says the new standards are designed to help countries build more effective, equitable, and comprehensive [https://www.brandsreviews.com/search?keyword=treatment%20programs treatment programs].&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Science continues to prove that the old adage &amp;quot;you are what you eat&amp;quot; is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your &amp;quot;gut microbiota.&amp;quot; They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;1. Unable to lose weight and keep it off? 2. Struggling to fight cravings? 3. Sick of starving yourself for weight loss? 4. Baffled as to why no diet seems to really work for you? Depending on the composition of your gut microbiome, your microbes can either boost your health or weigh you down (figuratively and literally). The good news is this: You have control over these little guys with every bite you eat. Diet has the power to change the landscape of your gut microbiome. So, if you’ve tried multiple diets and can’t seem to get the results you want, it’s time to look into your gut microbiome.Will You Lose Weight Naturally on an Individualized Diet? If you’ve been struggling to lose weight and keep it off - it could be your gut microbiome. While Viome doesn’t guarantee weight loss, it has been an exciting result many of our customers have reported. &amp;quot;Fiona’s update day 37!&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>ArnoldOquinn6</name></author>
	</entry>
	<entry>
		<id>https://rememberingbaltimore.net/index.php?title=Glucagon-like-peptide-1_Receptor_Expression_In_Normal_And_Diseased_Human_Thyroid_And_Pancreas&amp;diff=20071</id>
		<title>Glucagon-like-peptide-1 Receptor Expression In Normal And Diseased Human Thyroid And Pancreas</title>
		<link rel="alternate" type="text/html" href="https://rememberingbaltimore.net/index.php?title=Glucagon-like-peptide-1_Receptor_Expression_In_Normal_And_Diseased_Human_Thyroid_And_Pancreas&amp;diff=20071"/>
		<updated>2026-09-10T01:21:27Z</updated>

		<summary type="html">&lt;p&gt;ArnoldOquinn6: Created page with &amp;quot;&amp;lt;br&amp;gt;The present report is based on an extensive immunohistochemical study of the GLP1R status in human thyroid and pancreatic tissues with a specific and [https://www.news24.com/news24/search?query=well-validated%20monoclonal well-validated monoclonal] GLP1R antibody,24 and also compares and further validates the obtained data with in situ ligand binding. Because of previous studies in this field using poorly characterized antibodies,22, 25 we took particular care to use...&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;The present report is based on an extensive immunohistochemical study of the GLP1R status in human thyroid and pancreatic tissues with a specific and [https://www.news24.com/news24/search?query=well-validated%20monoclonal well-validated monoclonal] GLP1R antibody,24 and also compares and further validates the obtained data with in situ ligand binding. Because of previous studies in this field using poorly characterized antibodies,22, 25 we took particular care to use a thoroughly validated monoclonal antibody that specifically labels GLP1R-expressing cells while being negative for GLP1R-lacking cells,23, 24 and that has a superior immunohistochemical specificity compared with several other (commercial) GLP1R antibodies.23 As further proof of specificity and validation, we reported in the present study the results of specific GLP1R immunostaining in established human GLP1R targets such as endocrine pancreas or Brunner’s gland and compared these results with the data of an alternative method of GLP1R measurement, namely GLP1R autoradiography in the same tissues. Furthermore, we confirmed that immunohistochemistry of human insulinoma identifies true GLP1R by demonstrating the presence of such receptors in western blots of the same tissue.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Finally, we considered only membrane-bound GLP1R immunohistochemistry as truly specific, a basic request for  [http://tangxj.cn:6012/joannewilmoth7/3480990/wiki/A+Powerful+new+Force+is+Upending+how+Americans+buy+Food MedicGLP] the immunohistochemical characterization of all GPCRs,28 to which family the GLP1Rs also belong. The present results show definitely that the normal human thyroid, in particular the C cells, do not express GLP1R. C-cell hyperplastic human thyroids do not express GLP1R either. This is now well documented with two different methods: immunohistochemistry (in the present study) or autoradiography.2, 21 It confirms previous findings suggesting a strong species difference in the GLP1R expression in the thyroid, with high levels in normal and hyperplastic rat thyroids but with complete absence of such receptors in the human organ.2, 21 The lack of GLP1R in the human thyroid in the present study is in contrast with the immunohistochemistry study by Gier et al22 that showed the presence of immunostained GLP1R in the human thyroid. Conversely, a minority of sporadic medullary thyroid carcinomas, namely 2/10 (20%), did express a measurable amount of GLP1R by immunohistochemistry in our study.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Interestingly, the 10 familial medullary thyroid carcinomas of the MEN 2 type, however, were all found to be negative for these receptors. The present study indicates that not only insulin-producing cells in the islets express GLP1R, but that the latter can also be expressed by virtually all insulin-producing cells in the pancreas. This is true for the insulin cells in the PP-rich areas (the PP cells, however, are GLP1R negative); it is true for the single insulin cells distributed throughout the pancreas and it is also true for the insulin-producing endocrine cells localized in the pancreatic ducts. It is therefore probable that GLP1 will have a similar physiological role on insulin in the islet cells, as currently believed, as in all the other nonislet insulin-producing pancreatic cells, through specific GLP1R. This statement can also be extended to the role of the GLP1-like drugs used for diabetes treatment,  [https://oistinprojects.xyz/index.php/Affordable_GLP-1_Peptide_Therapy_For_Weight_Loss_In_Miami MedicGLP] targeted to these different types of insulin-producing cells. In addition to insulin-producing islet cells, the somatostatin-producing islet cells also express GLP1R, whereas glucagon-producing cells appear to lack such receptors.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;As reported previously, we confirm autoradiography and immunohistochemistry data2, 24 showing that human pancreatic acini do express GLP1R, although in much lower density than the insulin-producing cells. As opposed to the small population of GLP1-expressing endocrine cells, the fact that a large part of the pancreatic acinar population expresses GLP1R, even in low density, indicates that there is a considerable amount of nonendocrine GLP1R in the pancreas, for which a physiological role is not yet known. A marginal observation of this study is that acinar GLP1Rs seem to be reduced in chronic pancreatitis and in ductal pancreatic carcinoma samples as opposed to insulinoma samples. A similar observation was made previously with quantitative GLP1R autoradiography.2 Interestingly, in an animal model of pancreatitis, it was recently found that, contrary to the present data, GLP1Rs were increased in acini and ducts.29 This discrepancy may suggest once more that animal models may differ from settings in humans, making extrapolations from animals to humans difficult.11, 21 Interestingly, Gier et al25 did not detect GLP1R in human acini with their immunohistochemistry protocol.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;The pancreatic duct epithelial cells in any of the tested samples did not express GLP1R, with the exception of occasional endocrine insulin-producing cells. The absence of GLP1R is in agreement with the results of another immunohistochemistry study,24 an autoradiography study,2 and of an mRNA study,11 but is in conflict with the study by Gier et al25 showing GLP1R in ducts by immunohistochemistry. As the validation of the antibody used in the study by Gier et al25 was incomplete, we may assume that the convergent results of the four other studies showing absence of GLP1R in human duct epithelial cells correspond more closely to the reality. This implies that the normal ducts would not be a potential target for GLP1 drugs during diabetes therapy. The tissues that by far express the highest levels of GLP1R are specific neuroendocrine tumors of the pancreas, the benign insulinomas. This was discovered a decade ago by receptor autoradiography.3 It led subsequently to the successful development of in vivo targeting of insulinomas by using radiolabeled exendin analogs.7, 8, 9 The present study shows for the first time that it is possible to perform immunohistochemistry to easily diagnose the presence of GLP1R in these tumors in formalin-fixed tissues.&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>ArnoldOquinn6</name></author>
	</entry>
	<entry>
		<id>https://rememberingbaltimore.net/index.php?title=When_Used_In_This_Press_Release&amp;diff=19810</id>
		<title>When Used In This Press Release</title>
		<link rel="alternate" type="text/html" href="https://rememberingbaltimore.net/index.php?title=When_Used_In_This_Press_Release&amp;diff=19810"/>
		<updated>2026-09-09T17:02:30Z</updated>

		<summary type="html">&lt;p&gt;ArnoldOquinn6: Created page with &amp;quot;&amp;lt;br&amp;gt;Shanghai, 22 September 2021 - GLP announced today that it has reached a $1.75 billion first close for GLP China Logistics Fund III (&amp;quot;GLP CLF III&amp;quot;) to develop the next generation of modern and environmentally-friendly logistics facilities in China, including smart warehouses with integrated technologies to meet evolving customer requirements. GLP CLF III is the third vintage of the firm’s flagship discretionary commingled logistics development fund series and is tar...&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;&amp;lt;br&amp;gt;Shanghai, 22 September 2021 - GLP announced today that it has reached a $1.75 billion first close for GLP China Logistics Fund III (&amp;quot;GLP CLF III&amp;quot;) to develop the next generation of modern and environmentally-friendly logistics facilities in China, including smart warehouses with integrated technologies to meet evolving customer requirements. GLP CLF III is the third vintage of the firm’s flagship discretionary commingled logistics development fund series and is targeting $2 billion of total equity commitments which is expected to reach as much as $5 billion of assets under management (&amp;quot;AUM&amp;quot;) when fully deployed. Investor appetite for GLP CLF III has been overwhelmingly strong and the equity raised during the first close is from leading institutional investment [https://www.ft.com/search?q=partners partners] across North America, Asia, Europe and the Middle East, the majority of whom are existing GLP investors. The CLF series of development funds was launched by GLP in 2013 and the two predecessor funds - GLP CLF I and GLP CLF II - will deliver a combined 15 million square meters (sqm) (150 million square feet) across 150 parks in 40 cities. With the addition of [https://wideinfo.org/?s=GLP%20CLF GLP CLF] III, GLP manages more than $7 billion of discretionary equity for logistics real estate development in China, more than any other private real estate manager.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;As the leading warehouse logistics provider in the country, GLP has an extensive portfolio of logistics assets and land  [https://git.0411.ru/sheril8198977/5919medic-glp-website/wiki/When+used+in+this+Press+Release MedicGLP Official] holdings with total GFA in excess of 47 million square meters (&amp;quot;sqm&amp;quot;) and real estate AUM of over US$45 billion in China. Teresa Zhuge, Executive Vice Chairman of GLP China, said, &amp;quot;GLP CLF III is indicative of the continued investor appetite for modern logistics in China. The scale which GLP operates enables us to deploy capital efficiently to build a resilient portfolio of next generation of logistics facilities with modern solutions and integrated technologies that contribute to economic growth and job creation in surrounding communities. Led by customer demand, over the past 12 months GLP has delivered more than 3.2 million sqm of newly built, high-specification logistics assets in prime locations across China while signing 18.7 million sqm of new and renewal leases, up 53 percent year-on-year, leased to long term customers including leading eCommerce and 3PL players.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;GLP is a leading global investment manager and business builder in logistics, real estate, infrastructure, finance and related technologies. Our combined investing and operating expertise allow us to create value for our customers and investors. We operate across Brazil, China, Europe, India, Japan, the U.S. Vietnam and have more than US$120 billion in assets under management in real estate and private equity. We are committed to a broad range of environmental, social and governance (ESG) commitments that elevate our business, protect the interest of our shareholders and investors, support our employees and customers and enhance our local communities. This press release is not an offer of securities for sale or a solicitation of an offer to purchase securities. The information in this press release may not contain, and you may not rely on this press release as providing, all material information concerning the condition (financial or other), earnings, business affairs, business prospects, properties or results of operations of GLP or its subsidiaries.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;This release may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements include statements regarding the intent, belief and current expectations of GLP or its officers with respect to various matters. When used in this press release, the words &amp;quot;expects,&amp;quot; &amp;quot;believes,&amp;quot; &amp;quot;anticipates,&amp;quot; &amp;quot;plans,&amp;quot; &amp;quot;may,&amp;quot; &amp;quot;will,&amp;quot; &amp;quot;should,&amp;quot; &amp;quot;intends,&amp;quot;&amp;quot;foresees,&amp;quot; &amp;quot;estimates,&amp;quot; &amp;quot;projects,&amp;quot; and similar expressions, and the negatives thereof, are intended to identify forward-looking statements. Similarly, statements that describe objectives, plans or goals also are forward-looking statements. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Representative examples of these factors include (without limitation) general industry and economic conditions, interest rate trends, cost of capital and capital availability, availability of real estate properties, competition from other companies and venues for the sale/distribution of goods and services, shifts in customer demands, customers and partners, changes in operating expenses, including employee wages, benefits and training, governmental and public policy changes, and the continued availability of financing in the amounts and the terms necessary to support future business. You are cautioned not to place undue reliance on these forward-looking statements, which are based on the current view of management on future events and speak only as of the date of this press release. GLP does not undertake to revise forward-looking statements to reflect future events or circumstances. No assurance can be given that future events will occur, that projections will be achieved, or that GLP’s assumptions are correct.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Science continues to prove that the old adage &amp;quot;you are what you eat&amp;quot; is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your &amp;quot;gut microbiota.&amp;quot; They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?&amp;lt;br&amp;gt;&lt;/div&gt;</summary>
		<author><name>ArnoldOquinn6</name></author>
	</entry>
	<entry>
		<id>https://rememberingbaltimore.net/index.php?title=User:ArnoldOquinn6&amp;diff=19809</id>
		<title>User:ArnoldOquinn6</title>
		<link rel="alternate" type="text/html" href="https://rememberingbaltimore.net/index.php?title=User:ArnoldOquinn6&amp;diff=19809"/>
		<updated>2026-09-09T17:01:49Z</updated>

		<summary type="html">&lt;p&gt;ArnoldOquinn6: Created page with &amp;quot;Hi, everybody! My name is Rocky. &amp;lt;br&amp;gt;It is a little about myself: I live in Austria, my city of Oberwolbling. &amp;lt;br&amp;gt;It&amp;#039;s called often Northern or cultural capital of LOWER AUSTRIA. I&amp;#039;ve married 3 years ago.&amp;lt;br&amp;gt;I have two children - a son (Leslie) and the daughter (Retha). We all like Skydiving.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Take a look at my page :: [https://git.0411.ru/sheril8198977/5919medic-glp-website/wiki/When+used+in+this+Press+Release MedicGLP Official]&amp;quot;&lt;/p&gt;
&lt;hr /&gt;
&lt;div&gt;Hi, everybody! My name is Rocky. &amp;lt;br&amp;gt;It is a little about myself: I live in Austria, my city of Oberwolbling. &amp;lt;br&amp;gt;It&#039;s called often Northern or cultural capital of LOWER AUSTRIA. I&#039;ve married 3 years ago.&amp;lt;br&amp;gt;I have two children - a son (Leslie) and the daughter (Retha). We all like Skydiving.&amp;lt;br&amp;gt;&amp;lt;br&amp;gt;Take a look at my page :: [https://git.0411.ru/sheril8198977/5919medic-glp-website/wiki/When+used+in+this+Press+Release MedicGLP Official]&lt;/div&gt;</summary>
		<author><name>ArnoldOquinn6</name></author>
	</entry>
</feed>